Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.
OBJECTIVE
Mirasol pathogen reduction technology (PRT) for platelet concentrates uses riboflavin and ultraviolet light. Previously, we described increased metabolism and activation for PRT platelets stored in 100% plasma. To improve platelet quality, we resuspended platelets in a mixture of plasma and platelet additive solution (PAS).


METHODS
Single-donor platelets were resuspended in plasma and split into an untreated control and a PRT-treated single product. One hundred and fifty millilitre PAS (SSP+) was added to both. Over 7 days, we assayed pH, glucose consumption-, lactate production rate and CD62p with and without TRAP.


RESULTS
On day 5, PRT units showed a significantly lower pH (7.087 +/- 0.105 vs. 7.288 +/- 0.200) accompanied by a higher lactate production (0.104 +/- 0014 vs. 0.063 +/- 0.017 mmol/10(12)/h) and glucose consumption rate (0.039 +/- 0005 vs. 0.028 +/- 0.009 mmol/10(12) platelets/h). CD62p expression was higher in treated units (44.5 +/- 13.0 vs. 16.5 +/- 7.6%).


CONCLUSIONS
In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible
Janetzko
K
K
Institute of Transfusion Medicine and Immunology, Red Cross Blood Service Baden-Württemberg - Hessen, Heidelberg University, Medical Faculty of Mannheim, Germany. k.janetzko@blutspende.de
Hinz
K
K
Marschner
S
S
Goodrich
R
R
Klüter
H
H
D001639:Bicarbonates / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000528:radiation effects*; D001793:Blood Preservation / Q000379:methods*; D017848:Blood-Borne Pathogens / Q000528:radiation effects; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007773:Lactates / Q000378:metabolism; D019007:P-Selectin / Q000032:analysis; D019999:Pharmaceutical Solutions / Q000494:pharmacology*; D010949:Plasma; D015539:Platelet Activation / Q000187:drug effects; D012256:Riboflavin / Q000494:pharmacology*; D013535:Suspensions; D014466:Ultraviolet Rays
D001639:Bicarbonates; D007773:Lactates; D019007:P-Selectin; D019999:Pharmaceutical Solutions; D013535:Suspensions; D005947:Glucose; D012256:Riboflavin